Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuching Yang

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 12, 2022
FDA approval summary for lonafarnib (Zokinvy) for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathiesMari Suzuki, Linda J B Jeng, Solomon Chefo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2022
FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other RearrangementTimil H Patel, Leigh Marcus, M Naomi Horiba, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2022
FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic TherapyDonna Przepiorka, Robert Q Le, Alexei Ionan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2024
FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal CancerMichael J Fusco, Sandra J Casak, Sirisha L Mushti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2025
FDA Approval Summary: Vorasidenib for IDH-mutant Grade 2 Astrocytoma or Oligodendroglioma following surgeryMichael I Barbato, Amy K Barone, Stephanie L Aungst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2022
FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsElizabeth S Duke, Liza Stapleford, Nicole Drezner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2025
FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade GliomaSonia Singh, Diana Bradford, Somak Chatterjee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2021
FDA Approval Summary: Selumetinib for Plexiform NeurofibromaDenise Casey, Suzanne Demko, Arup Sinha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2025
FDA Approval Summary: Datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancerMelanie Royce, Mirat Shah, Lijun Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2025
US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment SettingJennifer J Gao, Tatiana M Prowell, Haley Gittleman, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 12, 2022
FDA approval summary for lonafarnib (Zokinvy) for the treatment of Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathiesMari Suzuki, Linda J B Jeng, Solomon Chefo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2022
FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 Fusion or Other RearrangementTimil H Patel, Leigh Marcus, M Naomi Horiba, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2022
FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic TherapyDonna Przepiorka, Robert Q Le, Alexei Ionan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 29, 2024
FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal CancerMichael J Fusco, Sandra J Casak, Sirisha L Mushti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2025
FDA Approval Summary: Vorasidenib for IDH-mutant Grade 2 Astrocytoma or Oligodendroglioma following surgeryMichael I Barbato, Amy K Barone, Stephanie L Aungst, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 16, 2022
FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsElizabeth S Duke, Liza Stapleford, Nicole Drezner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2025
FDA Approval Summary: Tovorafenib for Relapsed or Refractory BRAF-Altered Pediatric Low-Grade GliomaSonia Singh, Diana Bradford, Somak Chatterjee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 13, 2021
FDA Approval Summary: Selumetinib for Plexiform NeurofibromaDenise Casey, Suzanne Demko, Arup Sinha, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 27, 2025
FDA Approval Summary: Datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancerMelanie Royce, Mirat Shah, Lijun Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2025
US Food and Drug Administration Approval Summary: Ribociclib With an Aromatase Inhibitor in the Adjuvant Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Stage II and III High-Risk Early Breast Cancer Treatment SettingJennifer J Gao, Tatiana M Prowell, Haley Gittleman, et al.
Pageof 5